Breaking News

BeiGene Earns Merck Serono Milestone

May 5, 2014

BGB-283 BRAF inhibitor achieves clinical milestone

BeiGene, Co. has achieved a clinical milestone in its collaboration with Merck Serono for BGB-283, a second-generation BRAF inhibitor candidate in Phase I development, triggering a $5 million payment from Merck.
 
The companies entered the BGB-283, two-asset strategic collaboration in 2013. In December 2013, BeiGene began a Phase I trial of BGB-283 in patients with BRAF or KRAS mutations. The drug offers the potential to treat cancers that harbor BRAF mutations and/or aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway.
 
“We are very pleased to successfully reach this development milestone for BGB-283, as this exciting oncology candidate demonstrates the potential of BeiGene’s innovative translational research platform to deliver targeted therapeutics that address the unmet need of cancer patients,” said John V. Oyler, chief executive officer of BeiGene. “We look forward to working with Merck Serono as it continues to progress through the clinic.”

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems